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Abstract
Background: Thrombocytopenia is common in the intensive care unit. Potential mechanisms and etiologies
behind this phenomenon are multiple and often entangled. We assessed the effect of a systematic approach, using
routinely available tests, on the proportion of patients in whom the mechanism (primary objective) and etiology
(secondary objective) of thrombocytopenia in a mixed intensive care unit (ICU) could be identified.
Methods: Before-and-after study of all patients with thrombocytopenia was used. ‘Before’ group had no intervention.
New standard operating procedures for thrombocytopenia management were introduced. In the ‘After’ group, bone
marrow aspiration; determination of fibrinogen dosage, prothrombin time, factor V, D-dimers; assay of fibrin monomers,
ferritin, triglycerides, lactic acid dehydrogenase, aspartate transaminase, alanine aminotransferase, vitamin B12, folates,
reticulocytes, haptoglobin, and bilirubin were performed.
Results: In the Before group (n = 20), the mechanism (central, peripheral, or mixed) was identified in 10 % versus 83%
in After group (n = 23) (p < 0.001) (48% peripheral, 35% mixed). Before intervention, ≥1 etiology was identified in 15%
versus 95.7% in the After group (p < 0.001).
Conclusions: Systematic and extensive investigation using routine tests highlights the mechanisms and etiology of
thrombocytopenia in most cases.
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Background
Thrombocytopenia is the most common hemostatic dis-
order in the intensive care unit (ICU) with a prevalence
of around 50% [1,2]. It has been shown to be associated
with mortality through several factors, including platelet
nadir, rate of thrombocytopenia at ICU admission, rate
of thrombocytopenia on day 7, or lack of early recovery
from thrombocytopenia [2-6]. Thrombocytopenia is de-
fined as a platelet count of <150,000/mm3 [2] and it is
classified as severe if platelet count is <50,000/mm3,
which is the case for 2% to 15% of patients [7].
Thrombocytopenia is often classified as being caused
by a mechanism that is either central, peripheral, or
mixed. This distinction is also important in order to ap-
prehend the consequences of thrombocytopenia. Indeed,
there is greater tendency towards bleeding when the cause
is central. Conversely, there is an increased thrombotic
risk in case of a peripheral mechanism, such as platelet ac-
tivation, which can occur, for example, in the presence of
disseminated intravascular coagulation (DIC), frequently
encountered in the ICU [8,9]. Platelet activation is also in-
volved in cases of heparin-induced thrombocytopenia
(HIT) [1], antiphospholipid syndrome (APS), and throm-
botic microangiopathy (TMA), which, although rare, are
nonetheless not to be neglected, as underlined in the re-
cent guidelines for the management of thrombocytopenia
in the ICU setting [10]. Sometimes, a central or peripheral
mechanism can be highlighted but without any etiology
being identified.
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When a central mechanism is suspected, it is custom-
ary to perform bone marrow aspiration. Current guide-
lines [10] recommend that bone marrow aspiration
(BMA) should not be systematic, but rather should only
be considered in the absence of any obvious etiology of
thrombocytopenia or if other cell lines are affected.
However, thrombocytopenia in the ICU setting is often
multifactorial [9], frequently involving both central and
peripheral mechanisms. Thus, a peripheral etiology does
not exclude central involvement. In addition, it is rare
for thrombocytopenia to occur without concomitant
anemia in the ICU, regardless of whether the origin is
partially central or not. Therefore, in theory, BMA
should be discussed for all thrombocytopenic patients.
To the best of our knowledge, no before-and-after
study evaluating the impact of systematic investigation
of the etiology of thrombocytopenia, including BMA,
has ever been performed in the ICU setting to date.
In this context, our study aimed to determine the
impact of a systematic approach using routinely available
tests on the proportion of patients in whom the mecha-
nism of thrombocytopenia in the ICU could be identified.
The secondary objective was to determine the impact of
this systematic approach on the proportion of patients in
whom at least one etiology of thrombocytopenia could be
identified.
Methods
This before-and-after study was conducted in a 16-bed,
mixed ICU in a non-academic hospital (Chalon sur Saône,
France) between May and September 2012, in the context
of a review of professional practices. From 2 May to 2 July
2012, the first 20 consecutive patients who met the inclu-
sion criteria were included in the ‘Before group.’ From 22
July to 10 September 2012, after introduction of the new
approach, the first 23 consecutive patients who met the
inclusion criteria were included in the ‘After group.’ The
study was approved by the local ethics committee (Comité
de Protection des Personnes Est I, Dijon, France). The
study was considered to be part of routine care, and the
need for written informed consent was waived. All pa-
tients (or their next of kin in case of neurological deficit)
were informed about the study, and information about the
study was provided in written and oral format.
Patients
All patients hospitalized in the ICU during the study period
and with a confirmed diagnosis of thrombocytopenia, as
defined by a platelet count of <150,000/mm3, were eligible
for inclusion in the study.
Study design
Using a before-and-after study design, all ICU patients
with thrombocytopenia were managed according to the
conditions of their time period and consecutively in-
cluded. For patients in the ‘Before’ group presenting
thrombocytopenia in the ICU, management was left at the
physician's discretion. Physicians were free to perform as
many or as few investigations as they felt necessary and
were unaware that a study was taking place.
In July 2012, a review of professional practices was
undertaken at the initiative of the Chief of the ICU, fur-
ther to the publication of international guidelines for the
management of thrombocytopenia in the ICU [10]. The
new standard operating procedures for the management
of thrombocytopenia were introduced in the ICU. The
new procedures that all staff were instructed to follow
(i.e., the ‘action plan’) are described below. The 4 T score
[11-13] was calculated for all patients receiving heparin
at the time of inclusion or in the week prior to inclusion.
For patients with a 4 T score >3, testing for HIT anti-
bodies was performed, as HIT is unlikely for a 4 T score
of 0 to 3 [11]. The purpose of the new action plan, as
well as the exact procedures it recommended, was ex-
plained to all physicians and nurses working in the ICU
during interactive training sessions with a senior
physician experienced in the management of ICU
thrombocytopenia. The staff were aware that practices
would be evaluated further to the introduction of new
procedures but were not aware of the exact study objec-
tives. Subsequently, for all ICU patients in the ‘After’
group, physicians were required to follow the action plan
for all patients with a platelet count <150,000/mm3.
New action plan for the management of thrombocytopenia
(defined as platelet count <150,000/mm3) as explained to
the caregiving team
The following plasma assays must always be done
within 24 h after discovery of thrombocytopenia (plate-
let count <150,000/mm3 plasma):
 Prothrombin time (PT) (patient PT/controls PT)
 Fibrinogen
 Factor V
 D-dimers
 Assay of fibrin monomers present or not in soluble
complexes (Sta-Liatest FM)
 Ferritin
 Triglycerides
 Lactic acid dehydrogenase (LDH)
 Aspartate transaminase (AST)
 Alanine aminotransferase (ALT)
 Vitamin B12 and folates
In case of anemia, the same tests must be performed,
as well as measurement of plasma level of reticulocytes,
haptoglobin, and bilirubin.
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In patients with no history of thrombocytopenia, OR
in patients with a history of thrombocytopenia that has
worsened, OR if another cell line is affected (anemia or
leukopenia), bone marrow aspiration must be performed
within 72 h of the discovery of thrombocytopenia. Bone
marrow aspiration must systematically investigate the
mechanism of thrombocytopenia (central, peripheral,
mixed, undetermined) and criteria in favor of the pres-
ence of hemophagocytosis.
Assessments
Baseline characteristics were recorded for all patients,
namely, socio-demographic variables, Simplified Acute
Physiology Score (SAPS) II, Sequential Organ Failure
Assessment (SOFA) score, medical or surgical admis-
sion, platelet transfusion, and hemoglobin and leukocyte
counts at the time of diagnosis of thrombocytopenia.
We also recorded nadir platelet count, primary diag-
nosis, use of dialysis during thrombocytopenia, and
presence of cirrhosis. The course of platelet count
was recorded and classified as normalization in ICU
(achieving a count ≥ 150,000/mm3), improvement with-
out normalization in ICU, stability in ICU, or deterior-
ation in ICU. Platelet counts were performed every day
until normalization, discharge, or death (whichever oc-
curred first), and at the physician's discretion thereafter.
For each patient, in the ‘before’ and ‘after’ phases, all
data from the tests recommended in the action plan
were recorded when available.
For each patient, in the before and after phases, the
mechanism of thrombocytopenia was recorded, if identi-
fied (central, peripheral, mixed, unidentified) as well as
the underlying etiology(ies), if identified.
For DIC, the International Society for Thrombosis and
Hemostasis (ISTH) score was used.
Dilution was considered as involved if massive transfu-
sion or fluid infusion was performed, i.e., at least a blood
volume in 24 h or an half of blood volume in 4 h.
During smears examination, the percentage of histio-
cytes was established by counting histiocytes in a sample
of 200 nucleated cells. Phagocytosis of marrow cells was
defined as the presence of intact cells (as opposed to
cells debris), such as red cells, erythroblasts, platelets, or
white cells, in the cytoplasm of macrophages. Hemopha-
gocytosis was diagnosed when the percentage of histio-
cytes exceeded 2% of marrow nucleated cells and there
was more than one hemophagocytic cell per field.
If at least one criterion in favor of a central mechan-
ism was present, but none for a peripheral mechanism,
thrombocytopenia was classified as central. If at least
one criterion in favor of a peripheral mechanism was
present, but none in favor of central mechanism,
thrombocytopenia was classified as peripheral. If at least
one peripheral criterion and one central criterion were
observed, thrombocytopenia was classified as mixed. If
no criteria for either central or peripheral mechanisms
were observed, the mechanism was classified as
unidentified.
Statistical analysis
The primary endpoint was the percentage of patients in
whom the underlying mechanism of thrombocytopenia was
identified.
The secondary endpoint was the percentage of pa-
tients in whom at least one underlying etiology of
thrombocytopenia was identified.
Based on the observed rate of mechanism determin-
ation of 10% patients in the Before group, we calculated
that 17 patients in the After group would be sufficient to
show a significant difference of 40%, with at least 50%
patients in whom a mechanism could be identified, with
a power of 0.8 and an alpha risk fixed at 0.05 in a bilat-
eral situation.
Quantitative variables are described as median [inter-
quartile range (IQR)] and qualitative variables as number
(percentage). Patient characteristics were compared be-
tween the Before and After groups using the Mann-
Whitney U test or Fisher's exact test, as appropriate.
Statistical analysis was performed using SAS version
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Twenty patients were included in the before phase.
ISTH criteria in search of arguments in favor of DIC
were performed for 14 patients; detection of heparin-
induced anti-platelet antibodies was performed for two
patients; and one BMA was performed. No other inves-
tigations were performed in this group.
A total of 23 patients were included in the After
group. Of these, 22 underwent BMA, of which 3 could
not be interpreted as they were too diluted by excess
blood. The rest of the tests were carried out according
to the action plan. Six patients had a 4Ts score >3 and
underwent HIT antibodies testing; all were negative.
The baseline characteristics of the study population
are shown in Table 1. The population of the Before
group was included between 2 May and 2 July 2012.
During this period, 50 patients were admitted to the
ICU, giving a prevalence of thrombocytopenia of 40%.
In the After group, 23 patients were included between
22 July and 10 September 2012 out of 69 admissions
during the same period, giving a prevalence of
thrombocytopenia of 33.3 %. Twelve of the 20 patients
(60%) in the Before group and 19 out of 23 patients
(83%) in the After group had a platelet nadir lower than
80,000/mm3.
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Mechanisms
In the Before group, the mechanism of thrombocytopenia
(central vs peripheral) could not be determined in 90%
of patients, and in the remaining 10%, mixed thrombocytopenia
was retained.
The proportion of patients with a formally diagnosed
mechanism of thrombocytopenia increased from 10% to
83% between the two periods (p < 0. 001).
In the After group, a peripheral mechanism (without a
central mechanism associated) was identified in 11/23
patients (48%) and mixed origin in 8/23 (35%).
Etiologies
In the Before group, three patients (15%) had at least
one identified etiology. Hemophagocytosis was retained
as a cause of thrombocytopenia for one (5%) patient and
DIC for two (10%) patients. No specific treatment was
administered after identification of these phenomenons.
No heparin-induced thrombocytopenia was diagnosed.
In the After group, 21/23 (91.3%) patients had at least
one identified etiology. The percentage of etiology de-
termination increased by 76% between the two periods
(p < 0. 001). Etiologies were not mutually exclusive, and
9/23 (39%) patients had more than one etiology (two
etiologies for 4 patients, three for 3 patients, four
for 2 patients). The etiologies identified in the After
group are described in Table 2. No heparin-induced
thrombocytopenia was diagnosed. One patient with
intra-medullary hemophagocytosis received corticoste-
roids and intravenous immunoglobulins. Two others re-
ceived folate supplementation after deficiency was
detected. There was no other specific therapeutic im-
pact of the investigations in this group.
Course of platelet count and prognosis
Normalization of platelet count occurred for 16 patients
(80%) in the Before group and for 9 patients (39%) in
the After group (p = 0.01). The median [IQR] number of
days required to achieve normalization was 7.5 [5; 8.5]
days in the Before group and 5.5 [2; 7] days in the After
group (p = 0.55). The relationship between the course of
platelet count and prognosis in the After group is shown
in Table 3.
Platelet nadir and prognosis
Nadir platelet count was below 75,000/mm3 in all pa-
tients who died in the ICU. Three patients had a nadir
below 5,000/mm3 and these three died, but we also ob-
served very low nadir among survivors (17,000/mm3
minimum).
Bone marrow aspiration
In the Before group, one (5%) BMA was performed. In
11 patients in the After group, a central mechanism was
ruled out after BMA. Five (26.3%) specimens showed
significant hemophagocytosis. All five of these patients
had sepsis, and four were in shock with multiorgan
Table 1 Baseline characteristics of the two groups
Before group After group p value
(n = 20) (n = 23)
Age, median [IQR], years 63.5 [59;67] 69 [65; 84] 0.09
Female sex (%) 10 (50) 13 (56) 0.76
Nadir platelet count, median [IQR]/mm3 84,000 [52,000; 98,000] 34,000 [17,000; 76,000] 0.09
Hemofiltration (%) 8 (40) 14 (61) 0.22
Cirrhosis (%) 2 (10) 4 (17) 0.67
Sepsis (%) 20 (100) 17 (74) 0.23
Death in ICU (%) 6 (30) 15 (65) 0.03
SAPS II, median [IQR] 52.5 [41; 63] 72.5 [55; 78] 0.2
SOFA score, median [IQR] 11.5 [7; 15] 17 [9; 18] 0.1
Thrombocytopenia at admission to ICU (%) 10 (50%) 16 (70%) 0.23
Time from ICU admission to occurrence of thrombocytopenia, median [IQR], days 1.5 [1; 2] 1 [1; 2] NS
Platelet transfusion, n (%) 2 (10%) 1 (4.3%) 0.59
Medical admissions 10 (50%) 18 (78%) 0.06
IQR, interquartile range; ICU, intensive care unit; NS, non-significant.
Table 2 Etiologies in the After group
Mechanism Central (n = 8) Peripheral (n = 19)
Etiologies, n (%) Hemophagocytosis, 5 (21.7) DIC, 5 (21.7)
Folate deficiency, 2 (8.7) Dilution, 2 (8.7)
Myelodysplasia, 1 (4.3) Hemofiltration, 6 (26)
Hypersplenism, 1 (4.3)
Other, 12 (52.2)
DIC, disseminated intravascular coagulation; Other, other peripheral causes
(more specific etiology not provable).
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failure. One other specimen showed myelodysplasia in a
context of documented myelodysplastic syndrome. No
bone marrow infiltration by abnormal cells was ob-
served. One serious side effect occurred in the After
group further to sternal BMA, namely, compressive
pneumothorax in a context of irradiated sternum.
Hemophagocytosis and hemophagocytic
lymphohistiocytosis
We compared rates of classic biological parameters usu-
ally associated with hemophagocytic lymphohistiocytosis
(HLH) and outcomes between the patients who showed
hemophagocytosis on bone marrow aspirate and those
who did not. Death in ICU, platelet count normalization,
ferritin, aspartate transaminase, alanine aminotransfer-
ase, triglycerides, lactic acid, prothrombin time, fibrino-
gen, factor V, and leukopenia were not significantly
different between these two groups. Only nadir platelet
count was significantly lower in the intra-medullary
hemophagocytosis group with a median (IQR) at 7,000/
mm3 (5,000; 37,500) versus 65,000/mm3 (18,000; 78,000)
in the other group (p = 0.03).
Discussion
Our study demonstrated that systematic, extensive investi-
gations, even if only using tests that are available in rou-
tine practice, make it possible to identify in the majority of
cases whether thrombocytopenia in ICU patients is due to
central, peripheral, or mixed mechanisms (83% versus
10% when interventions were not systematic). Moreover,
routine investigation also makes it possible to identify at
least one etiology for a large majority of patients. The sys-
tematic biological work-up that was performed in the
After group in our study was established based on the
main etiologies usually described in the ICU and also on
the basis of the recent guidelines for the management of
thrombocytopenia in the ICU setting [10].
Not surprisingly, a peripheral mechanism is involved
in thrombocytopenia in most cases and is the sole cause
in almost 50%. Conversely, we observed no case caused
by a central mechanism alone, highlighting the import-
ance of peripheral causes in ICU patients, as previously
reported [9]. Our study confirms that this is valid even
when extensive investigations are performed to identify
the causal factors in all patients with thrombocytopenia.
The prevalence of thrombocytopenia in our study was
comparable to rates previously reported in the ICU set-
ting [1,2].
Our study is one of the few studies published to date
that investigates the causes of thrombocytopenia using a
rigorous etiological approach, with systematic imple-
mentation of BMA. It is the first to compare this sys-
tematic and extensive approach with the more classical
approach. Indeed, in the prospective study by Stephan
et al. [9] in surgical ICU patients, BMA was only per-
formed when other cell lines were affected, or in the ab-
sence of other obvious causes considered, and, in the
end, was only performed in 12 of the 52 patients in-
cluded. In the study by Thiolliere et al. [14], the authors
used a rigorous methodology with the extensive investiga-
tions, but they considered sepsis as one of the possible eti-
ologies while we did not consider sepsis as an etiology in
our study. Indeed, a lot of etiologies can be involved in
sepsis (DIC, hemophagocytosis, hypoplasia induced by in-
flammatory mediators, immune destruction, hypersplen-
ism). We did try to identify two etiologies classically
involved in thrombocytopenia during sepsis, namely DIC
and intra-medullary hemophagocytosis.
We noted one case with undetermined etiology in the
After group of our study. In the study by Thiolliere et al.
[14], there were six patients (2%) with undetermined eti-
ology. Indeed, some etiologies are difficult, if not impos-
sible, to establish because there is no specific test and
multiple etiologies may be associated. This is the case,
for example, for dilution, hypersplenism, and septic
consumption. Drug-induced thrombocytopenia is also
hard to affirm. Lim et al. [8] estimated its frequency at
18.8%, but in practice, this remains hard to confirm,
since the diagnostic criteria are based on an improve-
ment in platelet count when the drug is stopped. This
often occurs anyway when sepsis is resolved. As regards
DIC, no gold standard exists for the diagnosis of this
condition and is also difficult to affirm especially in liver
failure. We used the ISTH score in our study, in which
recent guidelines recommend for the diagnosis of DIC
[15]. To be fully comprehensive in highlighting possible
etiologies for thrombocytopenia, a routine test to detect
anti-platelet antibodies is lacking. However, it would
likely be of little use in clinical practice, since there are
no specific management approaches to be implemented
when anti-platelet antibodies are detected. For hemo-
phagocytosis, there is no consensus to date regarding a
cytologic definition. The diagnostic criteria we used here
were those used in a study by Stephan et al. [16] and
Strauss et al. [2], also performed in the ICU setting.
According to these criteria, five patients' BMA re-
vealed the presence of hemophagocytosis, but there is
no consensus regarding its management in the ICU,
Table 3 Course of platelet count and prognosis in the
After group
Survivors
n = 8
Non-survivors
n = 15
p value
No improvement 2 (25%) 9 (60%) 0.19
Early improvement (≤day 3) 6 (75%) 3 (20%) 0.02
Late improvement (>day 3) 2 (25%) 3 (20%) NS
Normalization 5 (62.5%) 4 (26.6%) 0.18
NS, non-significant.
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especially in case of septic shock, apart from symp-
tomatic and antibiotic treatment. Some authors advocate
immunosuppressant therapy (corticosteroids and etopo-
side) for HLH, while others are more reluctant [17-22].
Indeed, in most cases, hemophagocytic syndrome in
septic patients is reactive and does not require specific
therapies, since the treatment of the sepsis alone usually
leads to the resolution of hemophagocytosis. HLH is also
cited in the guidelines as a diagnosis that must be envis-
aged, because it requires specific investigations and
initiation of urgent targeted treatments. Moreover, clas-
sifying hemophagocytosis as an etiology with a central
mechanism is open to debate. Indeed, during HLH, bone
marrow richness is usually (but not always) normal or
increased [23], and hemophagocytosis is often both
intra- and extra-medullary. In our study, however, we
only documented intramedullary hemophagocytosis and
considered that any phenomenon occurring in the bone
marrow was associated with a central mechanism.
Bone marrow aspiration is an invasive diagnostic test
and is reportedly associated with a rate of serious ad-
verse reactions of <1% [24-28]. It is not recommended
systematically by current guidelines. The potential mor-
bidity associated with this technique underlines the need
to investigate its usefulness. Baughman et al. [29] re-
ported that BMA did not yield relevant information that
would have changed the management of the patient in
any of the cases in their study. In contrast, Stephan et al.
[9] reported that BMA made it possible to obtain a diag-
nosis in 10 cases out of 12. Thiollière et al. [14] reported
that BMA provided new information in 22% of the cases
and was likely to have an impact on patient management
in 11%. In our study, BMA had an therapeutic impact
for one patient who received a specific therapy for HLH.
It should be noted, however, that the only 10% of the pa-
tients with an identified mechanism in the Before group
did undergo BMA. Conversely, in the After group, the
83% of patients in whom the mechanism could be iden-
tified had BMA, and the 17% with no identified mechan-
ism did not have an interpretable BMA. Given that the
mechanism of thrombocytopenia is crucial to decision-
making as regards transfusion and anticoagulation, we
purport that this strategy has a major impact on patient
management. Indeed, the greatest risk incurred by cen-
tral thrombocytopenia is bleeding, while peripheral
thrombocytopenia tends to be due to thrombogenic phe-
nomena through platelet activation mechanisms. There-
fore, anticoagulation and platelet transfusion may be
either recommended or not recommended, depending
on the type of thrombocytopenia involved and its under-
lying mechanism. Currently, there is no other test avail-
able to distinguish between central and peripheral
mechanisms. Immature platelet fraction assessment
could be useful to avoid BMA in some cases but has
never yet been tested in the ICU setting [30-35]. Other
studies are necessary to determine the feasibility and the
impact of such a systematic approach on morbidity and
mortality.
Regarding the specific therapeutic impact of the inves-
tigations performed in the context of the Action plan,
which concerned only three patients in the After group,
we worked on the hypothesis that the thrombocytopenia
could be the result of a rare pathology, but for which an
established specific treatment exists, such as vitamin de-
ficiency, HIT, APS, or TMA. For example, although HIT
occurs in less than 1% of patients in the ICU setting
[36], the potential gravity justifies systematically search-
ing for this diagnosis and the same is valid for APS and
TMA.
Our study has several limitations that need to be ac-
knowledged. Firstly, it was performed at a single center
with a small number of patients, and the results may not
be generalizable to other institutions. Second, the use of
a before-after study design precludes any firm conclu-
sion regarding causality. Although the design of this
study does not allow comparison of outcomes between
the two populations, it appears nonetheless that the
After population had a higher mortality rate than the
Before group. SAPS II and SOFA score did not differ sig-
nificantly between periods, but this could be due to the
small number of patients included. We noted a border-
line significant trend towards more medical than surgical
admissions in the After group, which might partially ex-
plain the higher mortality in this group. However, it is
unlikely that heterogeneity in the severity of disease be-
tween the groups would impact on the main objective of
this study, considering that the platelet nadir did not dif-
fer significantly.
Conclusions
Our study shows that systematic and extensive investiga-
tions using routinely available tests make it possible to
distinguish between central, peripheral, and mixed
mechanisms in a large majority of thrombocytopenic pa-
tients. It also makes it possible to identify at least one
etiology of thrombocytopenia in most cases.
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